Antagonistic activity of ascorbic acid (vitamin C) on dopaminergic modulation: Apomorphine-induced stereotypic behavior in mice

Pharmacology

Volumn 77, Issue 1, 2006, Pages 38-45

  Deshpande, Chandrashekhar ^a   Dhir, Ashish ^a   Kulkarni, S K ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Apomorphine; Ascorbic acid; Dopamine; Modulation; Stereotypic behavior

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; APOMORPHINE; ASCORBIC ACID; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; RESERPINE; RISPERIDONE; SULPIRIDE; TALIPEXOLE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG ADDITIVE EFFECT; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; LAKA MOUSE; LOW DRUG DOSE; MALE; MOUSE; MOUSE STRAIN; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION; STEREOTYPY; SUPERSENSITIZATION;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; ANTIOXIDANTS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; ASCORBIC ACID; AZEPINES; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; HALOPERIDOL; MALE; MICE; RESERPINE; STEREOTYPED BEHAVIOR; SULPIRIDE;

EID: 33646518587     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092409     Document Type: Article

References (30)

1. 2 agonist binding. Life Sci 1992;51:921-930.
2. Thomas TN, Zemp JW: Inhibition of dopamine-sensitive adenylate cyclase from rat brain striatal homogenates by ascorbic acid. J Neurochem 1977;28:663-665.
3. Tolbert LC, Thomas TN, Middyagh LD, Zemp JW: Effects of ascorbic acid on neurochemical behavioral and physiological system mediated by catecholamines. Life Sci 1979;25:2189-2195.
4. Lazzarini M, Salum C, Del Bel EA: Combined treatment of ascorbic acid or α-tocopherol with dopamine receptor antagonist or nitric oxide synthase inhibitor potentiates cataleptic effect in mice. Psychopharmacology 2005;181:71-79.
5. Tolbert BM, Ward JB: Dehydroascorbic acid. Adv Chem Ser 1982;200:101-123.
6. 2 dopamine receptor binding. Neuroscience 1991;45:373-378.
7. 3H]-dopamine binding in striatum without inhibiting dopamine sensitive adenylate cyclase. Neurochem Int 1984;6:117-123.
8. Snyder SH, Bredt DS: Nitric oxide as a neuronal messenger. Trends Pharmacol Sci 1991;12:125-128.
9. Del Bel EA, da Silva CA, Guimarães FS, Bermudez-Echeverry M: Catalepsy induced by intrastriatal administration of nitric oxide synthase inhibitors in rats. Eur J Pharmacol 2004;485:175-181.
10. Abekawa T, Ohmori T, Koyama Y: Effects of NO synthase inhibition on behavioral changes induced by a single administration of methamphetamine. Brain Res 1994;666:147-150.
11. Stewart J, Deschamps SE, Amir S: Inhibition of nitric oxide synthase does not block the development of sensitization to the behavioral activating effects of amphetamine. Brain Res 1994;641:144-148.
12. Kulkarni SK: Experiments on intact preparations (in vivo studies). Handbook of Experimental Pharmacology, ed 3. New Delhi, Vallabh Prakashan, 1999, pp 117-121.
13. Iorio LC, Barnett A, Leitz FH, Houser VP, Korduba CA: SCH-23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. J Pharmacol Exp Ther 1983;226:462-468.
14. De Angelis L: The influence of ascorbic acid on the behavioral effects of haloperidol, amineptine and the combination in mice. Curr Ther Res 1991;49:267-273.
15. De Angelis L: Ascorbic acid and atypical antipsychotic drugs: modulation of amineptine-induced behaviors in mice. Brain Res 1995;670:303-307.
16. Rebec GV, Centore JM, White LK, Alloway KD: Ascorbic acid and the behavioral response to haloperidol: implications for the action of antipsychotic drugs. Science 1985;227:438-440.
17. Heikkila RE, Cabbart FS, Manzino L: Differential effects of ascorbic acid on the binding of dopamine agonists and antagonists to neostriatal membrane preparations. Correlation with behavioral effects. Res Commun Chem Pathol Pharmacol 1981;34:409-421.
18. Wambebe C, Sokomba E: Some behavioral and EEG effects of ascorbic acid in rats. Psychopharmacology 1986;89:167-170.
19. Tolbert LC, Thomas TN, Middyagh LD, Zemp JW: Ascorbate blocks amphetamine-induced turning behavior in rats with unilateral nigrostriatal lesions. Brain Res Bull 1979;4:43-48.
20. Pierce RC, Miller DW, Reising DB, Rebec GV: Unilateral neostriatal kainite but not 6-OHDA lesions block dopamine agonist-induced ascorbate release in the neostriatum of freely moving rats. Brain Res 1992;597:138-143.
21. Giannini AJ, Loiselle RH, DiMarzio LR, Giannini MC: Augmentation of haloperidol by ascorbic acid in phencyclidine intoxication. Am J Psychiatry 1987;144:1207-1209.
22. Sandyak R, Kanofsky JD: Vitamin C in the treatment of schizophrenia. Int J Neurosci 1993;68:67-71.
23. Heikkila RE, Manzino L, Cabbart FS, Hanly JG: Ascorbic acid and binding of DA agonists to neostriatal membrane preparations. Neuropharmacology 1983;22:135-137.
24. 3H]-agonist binding, pH dependence and lack of inhibition by ascorbic acid. Biochem Pharmacol 1982;31:3085-3091.
25. 2 receptors in dopamine depleted animals. Psychopharmacology (Berl) 1999;142:175-181.
26. 1 receptors. J Recept Res 1989;9:331-339.
27. 1 dopamine receptors. J Neurochemistry 1994;63:2093-2098.
28. Bishayee S, Balsubramanian AS: Lipid peroxide formation in rat brain. J Neurochem 1971;18:909-920.
29. 4 receptor subtypes and response to clozapine. Lancet 1993;341:116.
30. 2 receptor sensitivity of dopamine receptor antagonists possible therapeutic implications. Eur J Pharmacol 1993;236:483-486.